Inhibitory Effect Of Methionine-enkephalin Research Articles

The influence of the opioid pentapeptide methionine-enkephalin on seasonal and FSH-induced ovarian recrudescence in the gecko Hemidactylus frenatus

Although methionine-enkephalin (M-ENK) is implicated in the regulation of reproductive functions in vertebrates, its function in reptiles is little understood. This study aims to elucidate the role of M-ENK on seasonal and follicle stimulating hormone (FSH)-induced ovarian recrudescence in the gecko Hemidactylus frenatus. In the first experiment, administration of 5 µg M-ENK did not affect germinal bed activity or follicular developmental stages I, II, and III (previtellogenic) and IV (vitellogenic), but there were no stage V (vitellogenic) follicles in the ovary. However, there was a significant decrease in the mean numbers of oogonia and primary oocytes in the germinal bed associated with the complete absence of stage IV and V follicles in 25 µg M-ENK-treated lizards in contrast to experimental controls. Furthermore, there was a significant decrease in gonadotropin-releasing hormone - immunoreactive (GnRH-ir) content in the median eminence (ME) and pars distalis (PD) of the pituitary gland and sparse labelling of hypothalamic GnRH-ir neurons in 25 µg M-ENK-treated lizards. In the second experiment, treatment with FSH during the regression phase of the ovarian cycle resulted in the appearance of stage IV and V follicles, in contrast to their absence in the initial controls and treatment controls. However, treatment with 25 µg M-ENK + FSH did not result in the appearance of these follicles, indicating the inhibitory effect of M-ENK on FSH-induced ovarian recrudescence. These findings suggest that M-ENK inhibits the germinal bed and vitellogenic follicular growth in a dose-dependent manner, possibly mediated through the suppression of GnRH release in the ME and PD. In addition, M-ENK may also act at the level of the ovary in the gecko.

Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment

There is evidence that methionine enkephalin (MENK), an opioid peptide, promotes anti-tumor immune responses. In this study, the effect of MENK on colorectal cancer (CRC) and its mechanisms of action were examined in vivo. The intraperitoneal administration of 20 mg/kg MENK effectively inhibited MC38 subcutaneous colorectal tumor growth in mice. MENK inhibited tumor progression by increasing the immunogenicity and recognition of MC38 cells. MENK down-regulated the oncogene Kras and anti-apoptotic Bclxl and Bcl2, suppressed Il1b, Il6, iNOS, and Arg1 (encoding inflammatory cytokines), and increased Il17a and Il10 levels. MENK promoted a tumor suppressive state by decreasing the immune checkpoints Pd-1, Pd-l1, Lag3, Flgl1, and 2b4 in CRC. MENK also altered the immune status of the tumor immune microenvironment (TIME). It increased the infiltration of M1-type macrophages, CD8+T cells, and CD4+T cells and decreased the proportions of G-MDSCs, M-MDSCs, and M2-type macrophages. MENK accelerated CD4+TEM and CD8+TEM cell activation in the TIME and up-regulated IFN-γ, TNF-α, and IL-17A in CD4+T cells and Granzyme B in CD8+T cells. In addition, analyses of PD-1 and PD-L1 expression indicated that MENK promoted the anti-tumor immune response mediated by effector T cells. Finally, OGFr was up-regulated at the protein and mRNA levels by MENK, and the inhibitory effects of MENK on tumor growth were blocked by NTX, a specific blocker of OGFr. These finding indicate that MENK remodels the TIME in CRC to inhibit tumor progression by binding to OGFr. MENK is a potential therapeutic agent for CRC, especially for improving the efficacy of immunotherapy.

Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro.

Presynaptic modulation of synaptic transmission in rat subthalamic nucleus (STN) neurons was investigated using whole-cell patch-clamp recordings in brain slices. Evoked GABAergic inhibitory postsynaptic currents (IPSCs) were reversibly reduced by methionine enkephalin (ME) with an IC(50) value of 1.1 +/- 0.3 microM. The action of ME was mimicked by the mu-selective agonist [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO), and was partially blocked by the mu-selective antagonists naloxonazine and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH(2) (CTAP). Evoked GABA(A) IPSCs were also inhibited by the delta-selective agonist [D-Pen(2,5)]-enkephalin (DPDPE), but not by the kappa-selective agonist (+)-(5 alpha,7 alpha,8 beta)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide (U-69593) and the orphan receptor agonist orphanin FQ/nociceptin (OFQ). DPDPE-induced inhibition was completely blocked by the delta-selective antagonist N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH (ICI 174,864). ME, DAMGO and DPDPE increased the paired-pulse ratio of IPSCs. Evoked excitatory postsynaptic currents (EPSCs) were reversibly reduced by ME with an IC(50) value of 0.35 +/- 0.14 microM. Inhibition by ME was associated with an increase in the paired-pulse ratio of EPSCs. The action of ME was mimicked by DAMGO, and blocked by naloxonazine. DPDPE had little effect on evoked EPSCs. Neither U-69593 nor OFQ had any effect. ME significantly decreased the frequency of spontaneous miniature EPSCs (mEPSCs) without change in their amplitude. The action of ME was mimicked by DAMGO. DPDPE had no effect. The presynaptic voltage-dependent potassium conductance blocker 4-aminopyridine (4-AP, 100 microM) abolished the inhibitory effects of ME on evoked IPSCs and EPSCs. In contrast, 4-AP only partially blocked the actions of baclofen. These results suggest that opioids inhibit inhibitory synaptic transmission in the STN through the activation of presynaptic mu- and delta- receptors. In contrast, inhibition of excitatory synaptic inputs to the STN occurs through the activation of only mu-receptors. Both inhibitions may be mediated by blockade of voltage-dependent potassium conductance.

Inhibitory effects of opioids on voltage-dependent Ca 2+ channels and catecholamine secretion in cultured porcine adrenal chromaffin cells

The inhibitory effects of opioids on voltage-dependent calcium channels (VDCCs) were investigated in cultured porcine adrenal chromaffin cells using whole-cell patch clamp technique. The effects of the opioid on [Ca 2+] i increase and catecholamine secretion induced by high K + were also examined in single cells by fura-2 microfluorimetry and amperometry. A depolarizing pulse to 0 mV (test pulse) from a holding potential of −80 mV evoked an inward barium current ( I Ba), which was reversibly inhibited by methionine-enkephalin. This inhibitory effect of methionine-enkephalin was abolished by naloxone. Selective agonists of opioid receptor subtypes (DAMGO: μ, DPDPE: δ, U50488: κ) dose-dependently inhibited I Ba. In inhibitory potency, the order was DAMGO>U50488>DPDPE. These agonists applied sequentially produced a reversible I Ba inhibition in the same cells. The inhibitory effect of DAMGO on I Ba almost disappeared in the presence of ω-conotoxin GVIA but not ω-agatoxin IVA plus nifedipine. Application of a conditioning prepulse to +100 mV prior to the test pulse partly retrieved the I Ba inhibition by DAMGO, suggesting the involvement of voltage-sensitive components in opioid-induced VDCC inhibition. Intracellular application of GDPβS or GTPγS as well as pretreatment with pertussis toxin significantly reduced the extent of I Ba inhibition induced by DAMGO. DAMGO reversibly inhibited the [Ca 2+] i increase and catecholamine release induced by high K +. RT-PCR revealed the expression of μ-, δ- and κ-opioid receptor mRNAs in cultured adrenal chromaffin cells. These results suggest that porcine adrenal chromaffin cells possess μ-, δ- and κ-opioid receptors and activation of opioid receptors mainly inhibits N-type VDCCs via pertussis toxin-sensitive G-proteins.

Opioid and GABA receptors involved in mediation and modulation of tonic and stimulus-evoked inhibition of a spinal reflex in the decerebrated and spinalized rabbit

The purposes of this study were to investigate: (i) the identity of the opioid peptide(s) mediating tonic and stimulus-evoked inhibition of the sural-medial gastrocnemius reflex of the decerebrated, spinalized rabbit and (ii) the modulation of these processes by endogenous GABA. The selective δ receptor antagonist naltrindole (100 nmol kg −1 i.v.), the GABA A blocker bicuculline (300 nmol intrathecal, i.th.), and the GABA B antagonist CGP 35348 (1 μmol i.th.) increased gastrocnemius reflexes to 150–160% of pre-drug values, whereas a sub-maximal dose of naloxone (30 nmol kg −1 i.v.) augmented reflexes to >500% of controls. Kelatorphan, an inhibitor of enkephalin metabolism (2 μmol i.th.), depressed gastrocnemius responses by 50% and potentiated the inhibitory effects of methionine enkephalin. Repetitive electrical stimulation of the superficial or common peroneal nerves inhibited reflexes for 15–20 min. This effect was significantly reduced by naltrindole and CGP 35348. It was not reduced by a low dose (30 nmol kg −1 i.v.) of naloxone or by bicuculline. When naloxone and naltrindole were combined at 30 nmol kg −1 each, stimulus-evoked inhibition was blocked. Given after bicuculline, naloxone at 100 nmol kg −1 i.v. abolished peroneal-evoked inhibition, but a dose of 300 nmol kg −1 was required to produce the same effect after CGP 35348. Kelatorphan augmented the depth and duration of inhibition evoked by peroneal nerve stimulation. These data are consistent with the involvement of enkephalin-like peptides in tonic and stimulus-evoked inhibition of the sural-gastrocnemius reflex. Tonic inhibition in rabbit spinal cord is dominated by opioids acting through μ receptors, whereas co-activation of δ, μ and GABA B receptors mediates stimulus-evoked inhibition. It is possible that GABA B receptors inhibit the release of spinal opioids while simultaneously supporting their actions at post-synaptic targets.

Pre- and postsynaptic inhibitory actions of methionine-enkephalin on identified bulbospinal neurons of the rat RVL.

The effects of methionine-enkephalin (ME) on visualized bulbospinal neurons of the rostral ventrolateral medulla (RVL) were characterized in thin slices at 32 degrees C using the whole cell patch-clamp technique. Thirty-five percent of the recorded neurons were found to be tyrosine hydroxylase immunoreactive (C1 neurons). In voltage-clamp recordings, ME (3 microM) induced an outward current in 66% of RVL bulbospinal neurons. A similar percentage of C1 and non-C1 neurons were opioid sensitive. The current induced by ME was inwardly rectifying, reversed close to the potassium equilibrium potential, and was blocked by barium. Most spontaneous postsynaptic currents recorded in these neurons were tetrodotoxin (TTX)-resistant miniature postsynaptic currents (mPSCs). Approximately, 75% of mPSCs had rapid kinetics (decay time = 4.7 ms) and were glutamatergic [miniature excitatory postsynaptic currents (mEPSCs)] because they were blocked by 6-cyano-7-nitroquinoxaline-2,3-dione (10 microM). The remaining mPSCs had much slower kinetics (decay time = 19.6 ms) and were GABAergic [miniature inhibitory postsynaptic currents (mIPSCs)] as they were blocked by gabazine (3 microM) but not by strychnine (3-10 microM). ME decreased the frequency of mEPSCs and mIPSCs by 69 and 43%, respectively. The inhibitory effects of ME were mimicked by the selective mu-opioid receptor agonist endomorphin-1 (EM, 3 microM) and were blocked by naloxone (1 microM). In the absence of TTX, excitatory PSCs evoked by focal electrical stimulation were isolated by application of gabazine and strychnine. EM reduced the amplitude of the evoked EPSCs by 41% without changing their decay time. We conclude that opioids inhibit the majority of RVL C1 and non-C1 bulbospinal neurons by activating a potassium conductance postsynaptically and by decreasing the presynaptic release of glutamate. These cellular mechanisms could explain the depressive cardiovascular effects and the sympathoinhibition produced by opioid transmitters in the RVL, in particular during hypotensive hemorrhage.

In vivo demonstration of a paracrine, inhibitory action of Met-enkephalin on adrenomedullary catecholamine release in the rat.

The present study was an attempt to assess the inhibitory effect of methionine-enkephalin (Met-Enk) on adrenal catecholamine release under in vivo conditions employing a microdialysis system. One adrenal gland of intact male rats was implanted with a microdialysis system. One day after surgery, the adrenal dialysis system was connected to a perfusion pump and Ringer solution or a Ringer solution containing Met-Enk, naloxone (Nal), or a combination of Met-Enk and Nal was used for dialysis; dialysate fractions were collected at 5-min intervals. Catecholamine secretion was stimulated by an iv injection of 1.4 mumol (200 micrograms) acetylcholine (Ach). Met-Enk-immunoreactive material in adrenal medulla extracts and dialysate fractions was analyzed by reverse phase HPLC combined with Met-Enk RIA. Under resting conditions, adrenal release rates of norepinephrine and epinephrine into the Ringer solution were constant. After Ach application secretion of both catecholamines increased about 2.7-fold. Within 10 min after the injection, catecholamine levels returned to baseline levels. Intra-adrenal application of Met-Enk reduced Ach-stimulated epinephrine, but not norepinephrine, secretion significantly; application of Nal did not affect Ach-stimulated catecholamine secretion in the initial fraction after Ach injection, but significantly prolonged amine secretion after the cholinergic stimulus. Application of Nal followed by a combined application of Met-Enk and Nal was without an effect on the amount of catecholamines released in the initial fraction after Ach injection compared to that in the control group. Thus, naloxone prevented the inhibitory effect of Met-Enk on Ach-stimulated CA release. HPLC analysis of adrenal medulla extracts followed by Met-Enk RIA revealed that several forms of Met-Enk are present in chromaffin cells, whereas in adrenal dialysates only one, albeit broad, signal of Met-Enk immunoreactivity was detectable. We demonstrate in vivo a paracrine or autocrine action of Met-Enk on Ach-stimulated catecholamine release by applying the peptide directly into the adrenal gland via a microdialysis system. We conclude that neuropeptides endogenous to the adrenal gland not only reduce the amplitude of catecholamine secretion in response to an Ach stimulus but, in addition, modulate the duration of catecholamine secretion. This is demonstrated by a prolonged catecholamine secretion if opiate receptors are blocked by Nal.

Enkephalin inhibits the release and action of secretin on pancreatic secretion in the dog.

1. Pancreatic bicarbonate and protein secretion as well as immuno-reactive plasma secretin concentration in response to a meal, duodenal acidification and exogenous secretin or octapeptide of cholecystokinin (OP-CCK) have been measured following administration of methionine-enkephalin in chronic pancreatic fistula dogs. 2. Methionine-enkephalin inhibited pancreatic responses to both exogenous hormones (secretin and OP-CCK) and to endogenous hormones released from the gut by food or duodenal acidification. 3. Naloxone, a potent opiate receptor antagonist, partly prevents this methionine-enkephalin-induced inhibition of pancreatic secretion suggesting that this effect might be mediated by opiate receptors. 4. The inhibitory effect of methionine-enkephalin on pancreatic response to endogenous stimulants was more pronounced than that to exogenous hormones and was accompanied by a significant reduction in plasma immuno-reactive secretin concentration. 5. This study indicates that methionine-enkephalin inhibits pancreatic secretion, at least in part, by suppressing the release of the intestinal hormones stimulating the exocrine pancreas.

A comparative study of the effect of methionine enkephalin upon the stereospecific binding of an opiate agonist and an antagonist in mice and rats

The synthetic enkephalins especially methionine enkephalin are more potent in inhibiting the stereospecific binding of 3H-dihydromorphine than that of 3H-naloxone in mouse brain homogenates. Methionine enkephalin is a more potent inhibitor of 3H-dihydromorphine binding in whole mouse brain homogenates than in washed mouse brain membranes. No difference was observed with regard to the inhibitory effect of methionine enkephalin on the binding of 3H-dihydromorphine in whole rat brain homogenates or washed rat brain membranes. The use of different radiolabelled drugs (agonist versus antagonist), different species (mouse versus rat) and/or the variation in the preparation (brain homogenates versus washed membranes) may account for the difference between the IC 50 of methionine enkephalin versus 3H-dihydromorphine and versus 3H-naloxone stereospecific binding. The increased inhibitory effect of methionine enkephalin when the supernatant was added to the washed brain membranes supports the hypothesis that methionine enkephalin may be one part of the real endogenous morphine ligand.